- Home
- Latest
- By speciality
- Policy
- Biology
- Bone
- Brain and nervous system
- Breast
- Colorectal and gastrointestinal
- Community
- Diagnostics
- Drug development
- Epidemiology and prevention
- Haematology oncology
- Head and neck
- Hepatobiliary pancreatic
- Lung and pleura
- Melanoma and skin
- Ovary and gynaecology
- Paediatric
- Prostate and urology
- Psycho social
- Radiotherapy
- Sarcomas
- Surgery
- Other
- By congress
- EACR 21
- MBCC 12
- EHA 2010
- ASCO 2010
- ELCC 2010
- AACR 2010
- EMCCC 2010
- EBCC 7
- DKK 2010
- ASH 2009
- SABCS 2009
- AORTIC
- NCRI
- ECCO 15 - ESMO 34
- 11th Milan Breast Cancer Conference 2009
- IMPAKT
- ASCO 2009
- AACR 2009
- SABCS 2008
- ASH 50th annual meeting 2008
- ESMO 33
- 10th Milan Breast Cancer Conference 2008
- EBCC 6 2008
- ECCO 14 2007
- By continent
- Latest technologies
- Education
- Most viewed
- View all
Breast, North America, SABCS 2009
Flash player required
You do not have the correct version of the flash player required to view this content. Click here to install the free Adobe flash player.
Prof Adam Brufsky - University of Pittsburgh Cancer Institute, USA
Bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer
RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. RIBBON-2 results demonstrated that adding bevacizumab to chemotherapy as a second-line treatment for metastatic breast cancer significantly improved progression-free survival. Official San Antonio Breast Cancer Symposium press conference.
Congress » SABCS 2009
Other Congress
Content is the view and comment of the speakers or author and not of sponsoring companies or organisations. Organisation logo does not indicate endorsement.
Comments on this video Report unsuitable comment
No comments have been made on this video yet, be the first to voice your opinion, use the form on the right.
Add a comment